Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BioDrugs
Published in: BioDrugs 1/2015

01-02-2015 | Letter to the Editor

Cost-Utility Analysis of Biologic Therapies to Treat Chronic Plaque Psoriasis in Italy: The Importance of Using Updated and Adequate Social Tariffs to Calculate Quality-Adjusted Life-Years

Authors: Luciana Scalone, Paolo A. Cortesi

Published in: BioDrugs | Issue 1/2015

Login to get access

Excerpt

Spandonaro et al. [1] conducted an interesting cost-utility analysis to estimate the incremental cost/QALY (quality-adjusted life-year) ratio of biologic therapy for the treatment of chronic plaque psoriasis, adopting the perspective of the Italian National Health Service. The use of QALYs in the analysis allowed the calculation to include a parameter of effects measured in terms of health-related quality of life (HR-QOL), which is a component of health that is significantly compromised in patients with chronic plaque psoriasis. …
Literature
1.
Spandonaro F, Ayala F, Berardesca E, Chimenti S, Girolomoni G, Martini P, et al. The cost effectiveness of biologic therapy for the treatment of chronic plaque psoriasis in real practice settings in Italy. BioDrugs. 2014;28:285–95.CrossRefPubMedCentralPubMed
2.
Scalone L, Cortesi PA, Ciampichini R, Belisari A, D’Angiolella LS, Cesana G, et al. Italian population-based values of EQ-5D health states. Value Health. 2013;16(5):814–22.CrossRefPubMed
3.
Badia X, Roset M, Herdman M, Kind P. A comparison of United Kingdom and Spanish general population time trade-off values for EQ-5D health states. Med Decis Mak. 2001;21:7–16.CrossRef
Metadata
Title
Cost-Utility Analysis of Biologic Therapies to Treat Chronic Plaque Psoriasis in Italy: The Importance of Using Updated and Adequate Social Tariffs to Calculate Quality-Adjusted Life-Years
Authors
Luciana Scalone
Paolo A. Cortesi
Publication date
01-02-2015
Publisher
Springer International Publishing
Published in
BioDrugs / Issue 1/2015
Print ISSN: 1173-8804
Electronic ISSN: 1179-190X
DOI
https://doi.org/10.1007/s40259-015-0117-6

Other articles of this Issue 1/2015

BioDrugs 1/2015 Go to the issue

Erratum

Erratum to: Vedolizumab: A Review of Its Use in Adult Patients with Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease

Review Article

Enzymes Approved for Human Therapy: Indications, Mechanisms and Adverse Effects

Letter to the Editor

Reply to Scalone and Cortesi: “Cost-Utility Analysis of Biologic Therapies to Treat Chronic Plaque Psoriasis in Italy: The Importance of Using Updated and Adequate Social Tariffs to Calculate QALYs”

Review Article

Neurotrophin Family Members as Neuroprotectants in Retinal Degenerations

Review Article

Peptide-Based Vaccination and Induction of CD8+ T-Cell Responses Against Tumor Antigens in Breast Cancer

Adis Drug Evaluation

Vedolizumab: A Review of Its Use in Adult Patients with Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease